The attention-enhancing effects of spearmint extract supplementation in healthy men and women: a randomized, double-blind, placebo-controlled, parallel trial.

Previous studies have demonstrated that chronic supplementation with a proprietary spearmint extract (PSE) can improve cognitive performance in individuals 50-70 years of age with age-related memory issues. In the present study, our hypothesis was that chronic supplementation of PSE would improve cognitive performance in young, active individuals. Using a randomized, double-blind, placebo-controlled, parallel design, healthy, recreationally active men and women (N = 142) received 900 mg of PSE or placebo (PLA) daily for 90 days. Cognition was assessed via cognitive test battery (CNS Vital Signs) that resulted in 10 cognitive domains. Sleep, mood, and quality of life were assessed via validated questionnaires. Measurements were evaluated on days 0, 7, 30, and 90 of supplementation. Significant (P < .05) treatment effects were observed for sustained attention, wherein PSE improved sustained attention vs PLA at day 30 (PSE: 33.3 ±â€¯0.54 vs PLA: 31.2 ±â€¯0.98; P = .001) and day 90 (PSE: 34.0 ±â€¯0.44 vs PLA: 32.7 ±â€¯0.75; P = .007). Significant (P < .05) treatment × visit interactions were observed for complex attention, wherein PSE improved complex attention compared to PLA at day 7 (PSE: 8.0 ±â€¯2.22 vs PLA: 7.6 ±â€¯0.57; P = .016). Significant (P < .05) improvements were observed in 2 individual tests: the shifting attention test and the 4-part continuous performance test. No significant differences were observed in mood, sleep, or quality of life. The current study demonstrates that chronic supplementation with 900 mg of PSE improves cognitive performance in a young, active population, further supporting PSE as an efficacious nootropic.

Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial.

BACKGROUND: Proprietary spearmint extract (PSE) containing a minimum 14.5% rosmarinic acid and 24% total phenolic content, has evinced positive effects on cognition in individuals aged 50-70 with memory impairment after chronic supplementation. To address the growing interest in connecting mental and physical performance, the present study examined whether the nootropic effects of PSE translate into changes in reactive agility following daily supplementation with PSE. METHODS: Utilizing a randomized, double-blind, placebo-controlled, parallel design, healthy, recreationally-active men and women (n = 142) received 900 mg of PSE or placebo (PLA) daily for 90 days. Reactive agility, our primary outcome, was determined by measuring the number of hits and average reaction time (ART) on a Makoto Arena II, a 3600 audio-visual device that measures stationary, lateral, and multi-directional active choice reaction performance. Safety was evaluated using complete blood count, comprehensive metabolic panel, and blood lipids. Measurements were evaluated on days 7, 30, and 90 of supplementation. RESULTS: An overall treatment effect (p = 0.019) was evident for increased hits with PSE on the stationary test with footplates, with between group differences at Day 30 (PSE vs. PLA: 28.96 ± 2.08 vs. 28.09 ± 1.92 hits; p = 0.040) and Day 90 (PSE vs. PLA: 28.42 ± 2.54 vs. 27.02 ± 3.55 hits; p = 0.002). On the same task, ART improved (treatment effect, p = 0.036) with PSE at Day 7 (PSE vs. PLA: 0.5896 ± 0.060 vs. 0.6141 ± 0.073 s; p = 0.049) and Day 30 (PSE vs. PLA: 0.5811 ± 0.068 vs. 0.6033 ± 0.055 s; p = 0.049). PSE also significantly increased hits (treatment effect, p = 0.020) at Day 30 (PSE vs. PLA: 19.25 ± 1.84 vs. 18.45 ± 1.48 hits; p = 0.007) and Day 90 (PSE vs. PLA: 19.39 ± 1.90 vs. 18.66 ± 1.64 hits; p = 0.026) for the multi-directional test with footplates. Significant differences were not observed in the remaining Makoto tests. PSE was well tolerated as evidenced by no effects observed in the blood safety panels. CONCLUSIONS: The findings of the current study demonstrate that consumption of 900 mg of PSE improved specific measures of reactive agility in a young, active population. TRIAL REGISTRATION: clinicaltrials.gov, NCT02518165 . Registered August 7, 2015 - retrospectively registered.

A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness and Safety of a Thermogenic Supplement in Addition to an Energy-Restricted Diet in Apparently Healthy Females.

The increasing interest in weight loss has seen a concurrent rise in the supplemental use of thermogenics to aid weight loss efforts. To date, the effectiveness and safety of supplemental proprietary blend thermogenics, in conjunction with high-protein energy-restricted diets have not been thoroughly evaluated. The purpose of this study was to investigate the efficacy of a low-calorie, high-protein diet with and without the concomitant use of a thermogenic supplement on body weight and body composition in apparently healthy females. Subjects were divided into three groups, Bizzy Diet+FitMiss Burn (BURN, N = 12), Bizzy Diet+Placebo (PLA, N = 13), and Control (CON, N = 14), and underwent two testing sessions separated by approximately 3 weeks. Resting blood pressure (BP), resting heart rate (RHR), clinical safety markers, body weight (BW), and body composition were assessed during each testing session. Repeated measures analysis of variance (ANOVA) revealed a significant effect for time relative to BW, total body fat mass (FM), leg FM, and trunk FM. Post hoc analysis revealed that the BURN and PLA groups experienced significant decreases in both BW and total body FM compared to CON (p <.05). There were no significant interactions for BP, RHR, or clinical safety markers over the course of the study. The Bizzy Diet, both with and without the addition of FitMiss Burn thermogenic, appears to be safe for short-term use and may lead to greater improvement in body composition and BW in an apparently healthy female population.

Effect of Caffeine on Golf Performance and Fatigue during a Competitive Tournament.

PURPOSE: This study aimed to determine the effect of a caffeine-containing supplement on golf-specific performance and fatigue during a 36-hole competitive golf tournament. METHODS: Twelve male golfers (34.8 ± 13.9 yr, 175.9 ± 9.3 cm, 81.23 ± 13.14 kg) with a United States Golf Association handicap of 3-10 participated in a double-blind, placebo-controlled, crossover design in which they played an 18-hole round of golf on two consecutive days (36-hole tournament) and were randomly assigned to consume a caffeine-containing supplement (CAF) or placebo (PLA). CAF/PLA was consumed before and after nine holes during each 18-hole round. Total score, drive distance, fairways and greens in regulation, first putt distance, HR, breathing rate, peak trunk acceleration, and trunk posture while putting were recorded. Self-perceived ratings of energy, fatigue, alertness and concentration were also recorded. RESULTS: Total score (76.9 ± 8.1 vs 79.4 ± 9.1, P = 0.039), greens in regulation (8.6 ± 3.3 vs 6.9 ± 4.6, P = 0.035), and drive distance (239.9 ± 33.8 vs 233.2 ± 32.4, P = 0.047) were statistically better during the CAF condition compared with those during PLA. Statistically significant main effects for condition (P < 0.05) and time (P < 0.001) occurred for perceived feelings of energy and fatigue. Compared with PLA, CAF reported more energy (P = 0.025) and less fatigue (P = 0.05) over the competitive round of golf. There were no substantial differences in HR or breathing rates, peak trunk acceleration, or putting posture between conditions or over the round (P > 0.05). CONCLUSIONS: A moderate dose (1.9 ± 0.3 mg · kg(-1)) of caffeine consumed before and during a round of golf improves golf-specific measures of performance and reduces fatigue in skilled golfers.

Site-specific thigh muscle loss as an independent phenomenon for age-related muscle loss in middle-aged and older men and women.

The purpose of this study was to examine the relationships between dual-energy X-ray absorptiometry (DXA)-determined appendicular lean mass (aLM) and ultrasound-measured thigh muscle thickness (MTH) ratio and between aLM or thigh MTH ratio and zigzag walking performance. Eighty-one middle-aged and older adults (41 men and 40 women) aged 50 to 74 years volunteered for the study. Approximately two thirds of the subjects (34 men and 17 women) carried out regular sports activity (at least >2 times a week) including running and cycling exercise. MTH was measured using B-mode ultrasound at two sites on the anterior (A50) and posterior (P50) aspects of the mid-thigh. A50:P50 MTH ratio was calculated to evaluate site-specific thigh muscle loss. aLM and percent body fat were also determined using a DXA. Men had lower body fat and higher aLM than women. Anterior and posterior thigh MTH as well as A50:P50 MTH ratio was higher in men than in women. Zigzag walking time was faster in men than in women. Anterior and posterior thigh MTH was positively (p < 0.001) correlated to aLM and aLM index in men and women. However, A50:P50 MTH ratio was not significantly correlated with aLM and aLM index in both sexes. There was no significant correlation between aLM index and zigzag walking time in men and women. A50:P50 MTH ratio was inversely (p < 0.05) correlated to zigzag walking time in both men and women. Our results suggest that thigh MTH ratio is independent of age-related muscle mass loss detected by aLM.

Skeletal muscle mass, bone mineral density, and walking performance in masters cyclists.

Exercise mode and intensity/duration are important factors for influencing muscle morphology and function as well as bone. However, it is unknown whether masters cyclists who undergo regular moderate- to high-intensity exercise maintain lower-body skeletal muscle mass (SM) and function and bone health when compared with young adults. The purpose of this study was to compare SM, areal bone mineral density (aBMD), and gait performance between masters cyclists and young adults. Fourteen male masters cyclists (aged 53-71 years) and 13 moderately active young men (aged 20-30 years, exercising less than twice a week) volunteered. The masters cyclists were all training actively (four to five times per week, ∼200 miles per week) for on average the last 17 years (range 7-38 years). Thigh SM was estimated from an ultrasound-derived prediction equation using muscle thickness (MTH). Appendicular lean mass (aLM) and aBMD were also estimated using dual-energy X-ray absorptiometry. There were no significant differences (p<0.05) in thigh SM, anterior and posterior thigh MTH ratio, or aLM between masters cyclists and young men. Maximum straight and zigzag walking times were also similar between groups. Lumbar spine (L1-L4) aBMD was not different between groups, but femoral neck aBMD was lower (p<0.05) in the cyclists than in the young men. Our results suggest that appendicular as well as site-specific thigh muscle loss with aging were not observed in masters cyclists. This maintenance of muscle mass in masters cyclists may preserve walking performance to similar levels as moderately active young adults. However, long-term cycling does not preserve femoral neck aBMD.